The onychomycosis treatment market is projected to witness robust growth by 2027 owing to high consumer demand in key regions across the globe. Moreover, enhanced research focus on the development of more effective treatment methods is speculated to further fuel market expansion through the forecast timeline.

Onychomycosis refers to an infection of the nail caused by certain microorganisms. Onychomycosis with longitudinal spikes in the nail has been found to be challenging to manage with oral drugs. Therefore, researchers have been exploring other treatment approaches for the condition.

For instance, in a July 2021 study published in The Journal of Dermatology found that 10% efinaconazole solution could be used as a first-line drug for treating longitudinal spikes associated with onychomycosis. As a result, mounting research efforts towards identifying optimal treatment routes has positively influenced the product landscape.

For detailed analysis, the onychomycosis treatment market has been segregated on the basis of test, treatment type, drug class, distribution channel, and region. Based on test, the market has been divided into candida onychomycosis, distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, and others.

The white superficial onychomycosis sub-segment accounted for around 13.9% market share in 2020 and is anticipated to expand at a steady pace over 2021-2027. Increasing cases of white superficial onychomycosis is set to drive segmental growth through the following years.

With respect to treatment type, the onychomycosis treatment market has been segmented into drug treatment and topical therapy. In 2020, the topical therapy sub-segment held nearly 40% share in the market and is estimated to observe substantial growth through 2027. Surging availability of various topical solutions is likely to bolster segmental adoption in the coming years.

In terms of drug class, the market has been categorized into allylamine, griseofulvin, azoles, and others. The azoles constituted for over 17% share in the market in 2020 and is projected to amass profitable gains by the end of 2027. Rising awareness pertaining to the benefits of azole drugs is speculated to propel segmental uptake over the forthcoming years.

From the perspective of distribution channel, the onychomycosis treatment market has been bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. The online pharmacies sub-segment was valued at more than USD 462 million in 2020 and is expected to progress at a considerable CAGR through the assessment timeframe. Prevalent trend of purchasing medicines through online pharmacies is slated to boost segmental expansion in the upcoming years.

On the regional spectrum, the Latin America onychomycosis treatment market surpassed a valuation of about USD 120 million in 2020 and is calculated to attain a sizable revenue share in the overall industry by the end of the forecast period. Improving healthcare infrastructure across LATAM is foreseen to stimulate regional market growth in the future.